... neurodegenerative disease Parkinson’s disease PD (Parkinson's disease) is characterized by some typical motor signs and symptoms (hypokinesia, bradykinesia, resting tremor, rigidity) that are caused by striatal dopamine depletion and improved by dopamine replacement therapy. The most effective dopaminergic...

... (Lis-1) neurodegenerative disease nuclear distribution protein E (NDE1) nuclear distribution protein E-like (NDEL1) Intracellular cargo transport is driven by myosin, kinesin and dynein motor proteins that can move directionally along actin filaments and microtubules. Myosins use actin...

... to the aetiology of various neurodegenerative diseases related to protein conformational disorders by causing the accumulation of mutant proteins and cellular toxicity. Combining the knowledge of autophagy dysfunction and the mechanism of drug action may thus be rational for designing targeted therapy. The present...

... disease. 1 To whom correspondence should be addressed (email sallward77@gmail.com ). 18 5 2012 © The Authors Journal compilation © 2012 Biochemical Society 2012 neurodegenerative disease tau tau toxicity AD (Alzheimer's disease) is a progressive neurodegenerative...

...@kcl.ac.uk ). 6 6 2008 © The Authors Journal compilation © 2008 Biochemical Society 2008 iron chelation metal ion neurodegenerative disease oxidative stress protein aggregation therapy A classification of neurodegeneration can be achieved on the basis of the principal...

...-1RA) ischaemia neurodegenerative disease stroke Inflammation is generally a beneficial response of an organism to infection but, when prolonged or inappropriate, it can be detrimental. Neuronal loss in acute (e.g. stroke and head injury) and chronic [e.g. multiple sclerosis and AD...

...K.J. Krishnan; A.K. Reeve; D.M. Turnbull A decline in mitochondrial function has long been shown to exist in neurodegenerative disease. Whether this decline is a secondary consequence of other factors or whether it causes the eventual death of a cell is unknown. In this review, we will discuss some...

... pertinent pharmacological targets to induce neuroprotection in chronic neurodegenerative diseases. 1 To whom correspondence should be addressed (email bordet@univ-lille2.fr ). 11 8 2006 © 2006 The Biochemical Society 2006 cerebral ischaemia neurodegenerative disease...

... in various neurodegenerative diseases. Many proteins have the ability to produce amyloid-like structures, including the pre-synaptic protein α-syn, which is found in Lewy bodies [ 1 ]. EM (electron microscopy) has been used to show that α-syn fibrils both in brain extracts and formed in vitro are rigid...

...L. Masino; A. Pastore A growing number of neurodegenerative diseases are caused by expansion of CAG trinucleotide repeats coding for polyglutamine. The presence of intranuclear inclusions in the affected neuronal cells has suggested a mechanism for pathogenesis based on protein misfolding...

... neurodegenerative disease plasticity microglia Biochemical Society Transactions (2002) Volume 30, part 2 Tissue plasminogen activator as a modulator of neuronal survival and function S. E. Tsirka' Department of Pharmacological Sciences, University Medical Center at Stony Brook, Stony Brook, NY I 1794-865 I...